Targeted treatment of metastatic breast cancer by PLK1 siRNA delivered by an antioxidant nanoparticle platform

Jingga Morry, Worapol Ngamcherdtrakul, Shenda Gu, Moataz Reda, David J. Castro, Thanapon Sangvanich, Joe Gray, Wassana Yantasee

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

Metastatic breast cancer is developed in about 20%to 30% of newly diagnosed patients with early-stage breast cancer despite treatments. Herein, we report a novel nanoparticle platform with intrinsic antimetastatic properties for the targeted delivery of Polo-like kinase 1 siRNA (siPLK1). We first evaluated it in a triple-negative breast cancer (TNBC) model, which shows high metastatic potential. PLK1 was identified as the top therapeutic target for TNBC cells and tumor-initiating cells in a kinomewide screen. The platform consists of a 50-nm mesoporous silica nanoparticle (MSNP) core coated layer-by-layer with bioreducible cross-linked PEI and PEG polymers, conjugated with an antibody for selective uptake into cancer cells. siRNA is loaded last and fully protected under the PEG layer from blood enzymatic degradation. The material has net neutral charge and low nonspecific cytotoxicity. We have also shown for the first time that the MSNP itself inhibited cancer migration and invasion in TNBC cells owing to its ROS- and NOX4-modulating properties. In vivo, siPLK1 nanoconstructs (six doses of 0.5 mg/kg) knocked down about 80% of human PLK1 mRNA expression in metastatic breast cancer cells residing in mouse lungs and reduced tumor incidence and burden in lungs and other organs of an experimental metastasis mouse model. Long-term treatment significantly delayed the onset of death in mice and improved the overall survival. The platform capable of simultaneously inhibiting the proliferative and metastatic hallmarks of cancer progression is unique and has great therapeutic potential to also target other metastatic cancers beyond TNBC.

Original languageEnglish (US)
Pages (from-to)763-772
Number of pages10
JournalMolecular Cancer Therapeutics
Volume16
Issue number4
DOIs
StatePublished - Apr 1 2017

Fingerprint

Triple Negative Breast Neoplasms
Nanoparticles
Small Interfering RNA
Antioxidants
Breast Neoplasms
Silicon Dioxide
Neoplasms
Lung
Neoplastic Stem Cells
Therapeutics
Tumor Burden
Polymers
Neoplasm Metastasis
Messenger RNA
Survival
Antibodies
Incidence

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Targeted treatment of metastatic breast cancer by PLK1 siRNA delivered by an antioxidant nanoparticle platform. / Morry, Jingga; Ngamcherdtrakul, Worapol; Gu, Shenda; Reda, Moataz; Castro, David J.; Sangvanich, Thanapon; Gray, Joe; Yantasee, Wassana.

In: Molecular Cancer Therapeutics, Vol. 16, No. 4, 01.04.2017, p. 763-772.

Research output: Contribution to journalArticle

Morry, Jingga ; Ngamcherdtrakul, Worapol ; Gu, Shenda ; Reda, Moataz ; Castro, David J. ; Sangvanich, Thanapon ; Gray, Joe ; Yantasee, Wassana. / Targeted treatment of metastatic breast cancer by PLK1 siRNA delivered by an antioxidant nanoparticle platform. In: Molecular Cancer Therapeutics. 2017 ; Vol. 16, No. 4. pp. 763-772.
@article{5e516c189e5846bfb0a1c2416d1818cf,
title = "Targeted treatment of metastatic breast cancer by PLK1 siRNA delivered by an antioxidant nanoparticle platform",
abstract = "Metastatic breast cancer is developed in about 20{\%}to 30{\%} of newly diagnosed patients with early-stage breast cancer despite treatments. Herein, we report a novel nanoparticle platform with intrinsic antimetastatic properties for the targeted delivery of Polo-like kinase 1 siRNA (siPLK1). We first evaluated it in a triple-negative breast cancer (TNBC) model, which shows high metastatic potential. PLK1 was identified as the top therapeutic target for TNBC cells and tumor-initiating cells in a kinomewide screen. The platform consists of a 50-nm mesoporous silica nanoparticle (MSNP) core coated layer-by-layer with bioreducible cross-linked PEI and PEG polymers, conjugated with an antibody for selective uptake into cancer cells. siRNA is loaded last and fully protected under the PEG layer from blood enzymatic degradation. The material has net neutral charge and low nonspecific cytotoxicity. We have also shown for the first time that the MSNP itself inhibited cancer migration and invasion in TNBC cells owing to its ROS- and NOX4-modulating properties. In vivo, siPLK1 nanoconstructs (six doses of 0.5 mg/kg) knocked down about 80{\%} of human PLK1 mRNA expression in metastatic breast cancer cells residing in mouse lungs and reduced tumor incidence and burden in lungs and other organs of an experimental metastasis mouse model. Long-term treatment significantly delayed the onset of death in mice and improved the overall survival. The platform capable of simultaneously inhibiting the proliferative and metastatic hallmarks of cancer progression is unique and has great therapeutic potential to also target other metastatic cancers beyond TNBC.",
author = "Jingga Morry and Worapol Ngamcherdtrakul and Shenda Gu and Moataz Reda and Castro, {David J.} and Thanapon Sangvanich and Joe Gray and Wassana Yantasee",
year = "2017",
month = "4",
day = "1",
doi = "10.1158/1535-7163.MCT-16-0644",
language = "English (US)",
volume = "16",
pages = "763--772",
journal = "Molecular Cancer Therapeutics",
issn = "1535-7163",
publisher = "American Association for Cancer Research Inc.",
number = "4",

}

TY - JOUR

T1 - Targeted treatment of metastatic breast cancer by PLK1 siRNA delivered by an antioxidant nanoparticle platform

AU - Morry, Jingga

AU - Ngamcherdtrakul, Worapol

AU - Gu, Shenda

AU - Reda, Moataz

AU - Castro, David J.

AU - Sangvanich, Thanapon

AU - Gray, Joe

AU - Yantasee, Wassana

PY - 2017/4/1

Y1 - 2017/4/1

N2 - Metastatic breast cancer is developed in about 20%to 30% of newly diagnosed patients with early-stage breast cancer despite treatments. Herein, we report a novel nanoparticle platform with intrinsic antimetastatic properties for the targeted delivery of Polo-like kinase 1 siRNA (siPLK1). We first evaluated it in a triple-negative breast cancer (TNBC) model, which shows high metastatic potential. PLK1 was identified as the top therapeutic target for TNBC cells and tumor-initiating cells in a kinomewide screen. The platform consists of a 50-nm mesoporous silica nanoparticle (MSNP) core coated layer-by-layer with bioreducible cross-linked PEI and PEG polymers, conjugated with an antibody for selective uptake into cancer cells. siRNA is loaded last and fully protected under the PEG layer from blood enzymatic degradation. The material has net neutral charge and low nonspecific cytotoxicity. We have also shown for the first time that the MSNP itself inhibited cancer migration and invasion in TNBC cells owing to its ROS- and NOX4-modulating properties. In vivo, siPLK1 nanoconstructs (six doses of 0.5 mg/kg) knocked down about 80% of human PLK1 mRNA expression in metastatic breast cancer cells residing in mouse lungs and reduced tumor incidence and burden in lungs and other organs of an experimental metastasis mouse model. Long-term treatment significantly delayed the onset of death in mice and improved the overall survival. The platform capable of simultaneously inhibiting the proliferative and metastatic hallmarks of cancer progression is unique and has great therapeutic potential to also target other metastatic cancers beyond TNBC.

AB - Metastatic breast cancer is developed in about 20%to 30% of newly diagnosed patients with early-stage breast cancer despite treatments. Herein, we report a novel nanoparticle platform with intrinsic antimetastatic properties for the targeted delivery of Polo-like kinase 1 siRNA (siPLK1). We first evaluated it in a triple-negative breast cancer (TNBC) model, which shows high metastatic potential. PLK1 was identified as the top therapeutic target for TNBC cells and tumor-initiating cells in a kinomewide screen. The platform consists of a 50-nm mesoporous silica nanoparticle (MSNP) core coated layer-by-layer with bioreducible cross-linked PEI and PEG polymers, conjugated with an antibody for selective uptake into cancer cells. siRNA is loaded last and fully protected under the PEG layer from blood enzymatic degradation. The material has net neutral charge and low nonspecific cytotoxicity. We have also shown for the first time that the MSNP itself inhibited cancer migration and invasion in TNBC cells owing to its ROS- and NOX4-modulating properties. In vivo, siPLK1 nanoconstructs (six doses of 0.5 mg/kg) knocked down about 80% of human PLK1 mRNA expression in metastatic breast cancer cells residing in mouse lungs and reduced tumor incidence and burden in lungs and other organs of an experimental metastasis mouse model. Long-term treatment significantly delayed the onset of death in mice and improved the overall survival. The platform capable of simultaneously inhibiting the proliferative and metastatic hallmarks of cancer progression is unique and has great therapeutic potential to also target other metastatic cancers beyond TNBC.

UR - http://www.scopus.com/inward/record.url?scp=85017020262&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85017020262&partnerID=8YFLogxK

U2 - 10.1158/1535-7163.MCT-16-0644

DO - 10.1158/1535-7163.MCT-16-0644

M3 - Article

C2 - 28138033

AN - SCOPUS:85017020262

VL - 16

SP - 763

EP - 772

JO - Molecular Cancer Therapeutics

JF - Molecular Cancer Therapeutics

SN - 1535-7163

IS - 4

ER -